Please login to the form below

Not currently logged in
Email:
Password:

Sensipar

This page shows the latest Sensipar news and features for those working in and with pharma, biotech and healthcare.

NICE set to back Parsabiv for kidney disease complication

NICE set to back Parsabiv for kidney disease complication

be treated with Amgen's older drug Sensipar/Mimpara (cinacalcet) - and provided Amgen supplies the drug at an agreed discount. ... exceed Sensipar's sales at its peak, although rising levels of payer pushback in the US and elsewhere has led others to

Latest news

  • Amgen's chronic kidney disease drug Parsabiv cleared in US Amgen's chronic kidney disease drug Parsabiv cleared in US

    Amgen's chronic kidney disease drug Parsabiv cleared in US. Sensipar follow-up is the first therapy to be approved for treatment of sHPT in 12 years. ... to be used in clinical practice, the monthly costs of Parsabiv and Sensipar should be comparable.".

  • Amgen wins European approval for Parsabiv Amgen wins European approval for Parsabiv

    Prior to that Parsabiv had been predicted to equal and potentially exceed Sensipar, which brought in more than $1.4bn last year, although it is starting to face  generic competition in ... Amgen says Sensipar only has around 25% market penetration,

  • FDA knocks back Amgen's chronic kidney disease treatment FDA knocks back Amgen's chronic kidney disease treatment

    FDA knocks back Amgen's chronic kidney disease treatment. Parsabiv was hoped to equal or exceed solid earner Sensipar. ... Sadly, Amgen failed to show that Sensipar could reduce the risk of death and cardiovascular events in patients in CKD patients on

  • Amgen's Sensipar follow-up clears phase III trial Amgen's Sensipar follow-up clears phase III trial

    Amgen's Sensipar follow-up clears phase III trial. AMG 416 meets objectives in hyperparathyroidism. ... One of the unsung heroes in Amgen's product portfolio is Sensipar/Mimpara for secondary hyperparathyroidism (HPT), which has grown fairly steadily

  • Amgen profits down on rising costs Amgen profits down on rising costs

    Among Amgen's other new products, Sensipar/Mimpara (cinacalcet) for hyperparathyroidism grew 19 per cent to $256m, while Xgeva and Prolia (both denosumab) for preventing bone fractures rose 72 per cent

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics